Bruker (NASDAQ:BRKR) Stock Gets Price Target Increase from Leerink Partners

Bruker (NASDAQ:BRKR) had its price target boosted by research analysts at Leerink Partners from $80.00 to $85.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Leerink Partners‘s price objective indicates a potential upside of 38.64% from the stock’s previous close.

A number of other equities analysts have also issued reports on the stock. Citigroup reduced their price target on shares of Bruker from $60.00 to $53.00 and set a “hold” rating for the company in a research report on Wednesday, August 5th. Guggenheim upped their price objective on shares of Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Barclays increased their price objective on shares of Bruker from $58.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. TD Cowen raised their target price on shares of Bruker from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Finally, Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has an average rating of “Moderate Buy” and an average price target of $60.57.

Bruker Stock Performance

Bruker stock traded up $3.25 during trading hours on Thursday, hitting $61.31. 2,012,693 shares of the stock traded hands, compared to its average volume of 2,182,166. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.92. The firm’s 50 day moving average price is $59.01 and its 200-day moving average price is $50.59. The stock has a market capitalization of $9.34 billion, a price-to-earnings ratio of -55.74, a P/E/G ratio of 1.70 and a beta of 1.26. Bruker has a 1 year low of $32.37 and a 1 year high of $68.98.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.14. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%. The firm had revenue of $874.00 million during the quarter, compared to analysts’ expectations of $865.16 million. During the same period last year, the business posted $0.45 earnings per share. The company’s revenue for the quarter was up 1.6% compared to the same quarter last year. As a group, equities analysts expect that Bruker will post 2.12 EPS for the current fiscal year.

Insider Activity at Bruker

In other news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the sale, the vice president owned 134,806 shares of the company’s stock, valued at $7,127,193.22. This trade represents a 1.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 27.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Bruker

Several large investors have recently made changes to their positions in the company. Global Retirement Partners LLC purchased a new stake in shares of Bruker during the 2nd quarter worth about $38,000. Provenance Wealth Advisors LLC acquired a new stake in shares of Bruker during the 3rd quarter valued at about $52,000. Root Financial Partners LLC purchased a new position in shares of Bruker in the 3rd quarter valued at about $57,000. Essential Partners LLC purchased a new position in shares of Bruker in the 1st quarter valued at about $36,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Bruker in the 2nd quarter valued at about $60,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.